Short Communication

Fraction Unbound for Liver Microsome and Hepatocyte Incubations for All Major Species Can Be Approximated Using a Single-Species Surrogate^[S]

Received December 18, 2018; accepted February 5, 2019

ABSTRACT

It is well recognized that nonspecific binding of a drug within an in vitro assay (f_u) can have a large impact on in vitro to in vivo correlations of intrinsic clearance. Typically, this value is determined experimentally across multiple species in the drug-discovery stage. Herein we examine the feasibility of using a single species (rat) as a surrogate for other species using a panel of small molecules representing highly diverse structures and physiochemical classes. The study demonstrated that 86% and 92% of the tested compounds measured in the mouse, dog,

monkey, and human were within 2-fold of rat values for f_u in microsomes and hepatocytes, respectively. One compound, amiodarone, exhibited unique species-dependent binding where the f_u was approximately 10-fold higher in human microsomes and 20-fold higher in human hepatocytes compared with the average of the other species tested. Overall, these data indicate that using a single species (rat) f_u as a surrogate for other major species, including humans, is a means to increase the throughput of measuring nonspecific binding in vitro.

Introduction

In small-molecule drug discovery, microsomal and hepatocyte stability assays are commonly used to predict in vivo metabolic clearance by using various in vitro to in vivo correlation (IVIVC) methods (Obach, 1999; Austin et al., 2002). It is well recognized that nonspecific binding of the test compound within an in vitro assay incubation, or fraction unbound in an incubation ($f_{u,inc}$), can have a large impact on these predictions (Obach, 1999; Heuberger et al., 2013). Further, fraction unbound in microsomes ($f_{u,mic}$) and hepatocytes ($f_{u,hep}$) is a critical parameter for improving intrinsic clearance estimations and, as such, is commonly measured. In addition, in vitro drug-drug interaction regulatory guidance documents (EMA, 2012; FDA, 2012, 2017) emphasize application of the free fraction in estimating drug-drug interaction potential for investigational new drug candidates. To address this, f_u will typically be measured across every species in which an in vitro clearance has been tested. Thousands of compounds may need to progress through the testing funnel in the drug-discovery stage, and thus the investigation of $f_{u,inc}$ across multiple species can rapidly become a resource and labor-intensive endeavor, particularly with respect to reagents, in addition to the instrument and analyst time required.

To increase the efficiency of high-throughput testing of this critical in vitro parameter, we asked the following question: Are there meaningful interspecies differences in microsomal and hepatocytic f_u such that testing all species—mouse, rat, dog, monkey, and human—is warranted? To date, a limited number of published reports describe

microsomal and hepatocyte binding that has been rigorously investigated across species. Obach (1997) demonstrated that $f_{u,mic}$ was equivalent across four species (i.e., rat, dog, monkey, and human) using three probe compounds: imipramine, propranolol, and warfarin. Zhang et al. (2010) also evaluated microsomal binding in these same species using several (32) clinical drugs and observed no species-specific differences with respect to $f_{u,mic}$. In a more recent publication, the unbound fraction in rat liver homogenate ($f_{u,liver}$) for a variety (22) of compounds was consistent with $f_{u,liver}$ and cellular fraction unbound ($f_{u,cell}$) across other species (Riccardi et al., 2018). Despite these findings, it remains common practice to evaluate nonspecific binding across multiple species. In this work, we systematically evaluated $f_{u,mic}$ and $f_{u,hep}$ in the prototypical preclinical species (mouse, rat, dog, monkey, and human) for a highly diverse panel of small molecules, ranging in charge state, such as acid, base, neutral, or zwitterion, and lipophilicity. Our findings demonstrate that rat liver microsomes and hepatocytes are a suitable surrogate for determining $f_{u,inc}$ in other species, including humans.

Materials and Methods

Materials. A library containing the 36 compounds tested (listed in Table 1) was purchased as 10 mM stock solution in dimethylsulfoxide (DMSO) from Selleck Chemicals (Houston, TX). Mouse (male CD-1) and rat (male Sprague-Dawley) liver microsomes with a pool size of 380 and 210 subjects, respectively, were purchased from Corning Life Sciences (Corning, NY). Dog (male beagle), monkey (male cynomolgus), and human (mixed gender, mixed race) liver microsomes with a pool size of 10, 3, and 50, respectively, were purchased from Gibco Biosciences (Dublin, Ireland). Male CD-1 (single donor), male Sprague-Dawley rat (single donor), male beagle dog (single donor), male cynomolgus monkey (single donor), and mixed sex human (50-donor pool) cryopreserved hepatocytes were purchased from Biorec-amation IVT

<https://doi.org/10.1124/dmd.118.085936>.

[S] This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: DMEM, Dulbecco's modified eagle medium; DMSO, dimethylsulfoxide; $f_{u,hep}$, fraction unbound in hepatocytes; $f_{u,inc}$, fraction unbound in an in vitro incubation; $f_{u,liver}$, fraction unbound in liver homogenate; $f_{u,mic}$, fraction unbound in liver microsomes; IVIVC, in vitro to in vivo correlation; LogD, partition coefficient of a molecule between octanol and buffer at pH 7.4; LogP, partition coefficient of a molecule between octanol and water.

TABLE 1

 $F_{u, \text{mic}}$ for 36 compounds across five species

A, B, N, and Z correspond to acid, base, neutral, and zwitterionic compound classes, respectively. Values represent a mean of triplicate determinations; %CV was $\leq 20\%$ for all compounds.

Compound	Class	LogD	Mouse	Rat	Dog	Monkey	Human
Bumetanide	A	-0.080	0.63	0.98	1.0	0.94	1.0
Cefazolin	A	-4.4	0.45	0.59	0.43	0.43	0.43
Cefoperazone	A	-1.1	0.79	0.53	0.55	0.78	1.0
Diclofenac	A	1.4	0.88	0.96	1.0	0.82	1.0
Fluvastatin	A	-2.2	1.0	1.0	1.0	0.78	1.0
Gemfibrozil	A	1.7	0.73	0.88	0.56	0.49	0.81
Glyburide	A	1.1	0.38	0.52	0.46	0.38	0.43
Ketoprofen	A	-0.16	0.59	0.6	0.63	0.67	0.74
Naproxen	A	0.35	0.61	0.77	0.49	0.31	0.39
Oxaprozin	A	0.090	0.16	0.24	0.19	0.11	0.28
Phenytoin	A	-0.71	0.5	0.495	1.0	0.87	1.0
Tenoxicam	A	-2.9	1.0	0.91	0.69	0.86	0.77
Amiodarone	B	5.9	0.0039	0.0046	0.0016	0.0027	0.035
Amitriptyline	B	2.7	0.24	0.21	0.26	0.21	0.18
Bupivacaine	B	2.9	1.0	0.99	0.45	0.66	0.85
Chlorpromazine	B	3.2	0.29	0.11	0.33	0.24	0.17
Clozapine	B	3.5	0.26	0.3	0.34	0.79	0.71
Disopyramide	B	-0.070	0.59	0.48	0.41	0.41	0.84
Haloperidol	B	2.9	0.47	0.63	0.57	0.50	0.35
Imatinib	B	2.5	ND	0.43	0.43	0.18	0.17
Imipramine	B	2.4	0.53	0.6	0.65	0.82	0.77
Metoprolol	B	-0.47	0.61	0.54	0.59	0.58	0.66
Nicardipine	B	4.6	0.067	0.12	0.18	0.098	0.13
Propranolol	B	0.79	0.2	0.26	0.21	0.23	0.3
Albendazole	N	3.0	1.0	1.0	0.51	0.93	1.0
Antipyrine	N	0.44	0.45	1.0	0.43	0.41	0.41
Dexamethasone	N	-4.6	1.0	1.0	0.94	0.91	0.67
Isradipine	N	3.7	0.66	0.71	0.86	0.64	0.27
Indapamide	N	2.0	0.79	0.53	0.55	0.78	1.0
Zidovudine	N	0.050	0.72	0.71	1.0	1.0	0.64
Doxorubicin	Z	-1.5	0.021	0.039	0.016	0.016	0.027
Levofloxacin	Z	-0.39	0.26	0.35	0.30	0.31	0.29
Methotrexate	Z	-5.1	0.018	0.025	0.028	0.010	0.040
Naltrexone	Z	1.6	0.84	0.85	0.73	0.81	0.59
Telmisartan	Z	3.49	0.56	0.65	0.54	0.58	0.56
Topotecan	Z	-0.32	0.88	0.68	0.61	0.59	0.59

(Baltimore, MD). Dulbecco's modified Eagle's medium (DMEM) was purchased from Gibco.

Liver Microsome Nonspecific Binding Using Ultracentrifugation. Liver microsome stocks (20 mg/ml protein content) were diluted in 100 mM potassium phosphate buffer, pH 7.4, to a final concentration of 0.25 mg/ml. To a 1 ml solution of microsomes, 1 μ l of a DMSO stock solution of test compound (0.5 mM) was added to provide a 0.5 μ M final concentration. The mixture of compound and microsomes was incubated for 45 minutes at 37°C. In triplicate, 200 μ l aliquots were then centrifuged at 37°C for 3 hours at 627,000g. An aliquot of supernatant (50 μ l) was removed and transferred to 50 μ l of 0.25 mg/ml blank microsomal mixture. For control (uncentrifuged) samples, 50 μ l of microsome/compound mixture was added to 50 μ l of blank microsomal filtrate. All samples were quenched with 0.3 ml of acetonitrile containing 10 μ M tolbutamide as internal standard. Samples were vortexed and centrifuged at 3220g for 20 minutes. Supernatants were analyzed by liquid chromatography-mass spectrometry as described for hepatocyte experiments to follow.

Hepatocyte Nonspecific Binding Using Ultracentrifugation. Cell suspensions (0.5×10^6 cells/ml) were prepared in 1 $\times$ DMEM buffer plus 1 mM L-glutamine. Suspensions were freeze-thawed one time, and cell viability ($\leq 10\%$) was confirmed by trypan blue exclusion. Compound stocks were prepared in DMSO and added to an 800 μ l hepatocyte suspension for a final concentration of 0.5 μ M (0.5% DMSO). After an equilibration for 15 minutes at 37°C, each suspension (200 μ l) was transferred to polycarbonate tubes (7×20 mm) in duplicate and centrifuged at 100,000 rpm for 3 hours at 37°C using an Optima TLX ultracentrifuge (Beckman Coulter, Pasadena, CA). To facilitate the calculation of unbound fraction, 50 μ l of initial spiked hepatocyte suspensions were added in duplicate to 50 μ l 1 $\times$ DMEM buffer and quenched with 300 μ l acetonitrile containing 1 μ M tolbutamide as an

internal standard. After centrifugation, 50 μ l of supernatant was removed and added to 1 $\times$ DMEM, and proteins were precipitated with acetonitrile containing internal standard. Samples were then centrifuged for 10 minutes at 3220g.

Liquid Chromatography-Tandem Mass Spectrometry and Data Analysis. Samples (1 μ l) were injected onto a Kinetex C18 column (2.6 μ m, 50×2.1 mm; Phenomenex, Torrance, CA) using a Shimadzu ultrafast-liquid chromatography system coupled to an AB Sciex Qtrap 5500 mass spectrometer. The mobile phases consisted of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) using a flow rate at 1 ml/min and a gradient as follows: 5% B for 0.8 minute, 99% B for 0.5 minute, and returned to 5% B to 1.5 minutes. Analytes were quantified using the analytical parameters described in the supplemental section (Supplemental Table 1). Compound peak areas were integrated using Analyst 1.6.2 software and normalized to the internal standard.

The unbound fraction was calculated using eq. 1:

$$\text{Unbound fraction, } F_u = \frac{\text{Ultracentrifuge supernatant at 3h}}{\text{Spiked microsome or hepatocyte suspension at 0h}} \quad (1)$$

Results and Discussion

Correction for the $f_{u, \text{inc}}$ in liver microsomes and hepatocytes is expected to improve IVIVC in preclinical species and thus more accurately predict human clearance. Consequently, free drug fraction is typically measured across multiple species. An alternative to a multispecies screening approach would be to select a representative species to measure f_u and use this value to scale cross-species, which could add significant value to small-molecule discovery research, as the proposed method described herein has the capability of decreasing experimental resource burden by up to 5-fold. Riccardi et al. (2018) recognized the utility of this approach. In their study, f_u data measured in liver homogenate suggested that a single-species surrogate (rat) may be appropriate to replace $f_{u, \text{inc}}$ determination in other species; however, to date, this observation has yet to be systematically tested mainly using a diverse library of small molecules in microsomes as well as hepatocytes isolated from all four major preclinical species in addition to humans.

In line with the Riccardi publication, we selected the rat as the comparator species to test our hypothesis. The rat is advantageous for two reasons. First, it is often the initial preclinical species to use for in vivo pharmacokinetic studies, so binding experiments are very routinely performed to inform IVIVC. Second, the cost associated with rat microsomes and hepatocytes are markedly less expensive compared with other species, particularly human. If $f_{u, \text{inc}}$ is indeed identical across all prototypic species, then the choice of comparator species will not impact the experimental results.

To assess the binding properties across a range of chemical space, we strategically selected a panel of 36 small molecules for investigation. Overall, each compound class (acid, base, neutral, and zwitterionic) was represented with at least six compounds and encompassed a range of lipophilicities (logD ranging from -4 to 6). Calculated logD values were determined using the ChEMBL algorithm developed by the European Bioinformatics Institute, which can be found at <https://www.ebi.ac.uk/chembl/>. Table 1 summarizes the values measured for $f_{u, \text{mic}}$ across five species: mouse, rat, dog, monkey, and human. As anticipated, $f_{u, \text{mic}}$ values across compounds were quite diverse, ranging from tightly bound to highly free ($f_{u, \text{mic}} = 0.0039-1, 0.0046-1, 0.0016-1, 0.0027-1$, and $0.027-1$ for the mouse, rat, dog, monkey, and human, respectively). For an interspecies comparison, we selected rat $f_{u, \text{mic}}$ as the comparator on the x-axes and plotted the fraction unbound of each preclinical species either mouse, dog, monkey, or human on the y-axes (Fig. 1). Using a 2-fold $\pm$ margin cutoff (dashed lines), these graphs demonstrate that most compounds tested (85% in total) fell within 2-fold of rat

Fig. 1. Comparison of fraction unbound ($f_{u,mic}$) in the mouse, rat, dog, or monkey and human liver microsomes for 12 acidic (closed circles), 12 basic (closed squares), six neutral (open diamonds), and six zwitterionic drugs (closed triangles). Solid and dashed lines represent lines of unity and 2-fold upper and lower bound limits, respectively.

measurements for the mouse, dog, monkey, and human (94%, 83%, 78%, and 83%, respectively). Further analysis by compound class also revealed that the average $f_{u,mic}$ fold difference for all species relative to the rat was consistently within 2-fold for all classes (Supplemental Fig. 1). These results indicate that using rat microsomal binding as a surrogate for all other species would provide a reasonable estimate to inform decisions in early drug discovery.

We then applied the same approach to test whether hepatocyte binding exhibited a similar trend. Table 2 shows the $f_{u,hep}$ values for the same compound library tested across all five species. In general, the free fraction of molecules was somewhat greater in hepatocytes compared with microsomes; however, similar trends overall were observed. Moreover, measured $f_{u,hep}$ values were just as diverse and mirrored that observed in microsomes ($f_{u,hep} = 0.0023$ –1, 0.0081–1, 0.0060–1, 0.0062–1, and 0.076–1 in the mouse, rat, dog, monkey, and human, respectively). Figure 2 shows the results of using the rat as the comparator species. Using a 2-fold margin cutoff above and below (dashed lines), the graphs indicate that a large majority of compounds (96% in total) fell within 2-fold of rat measurements for the mouse, dog, monkey, and human (89%, 97%, 100%, and 97%, respectively). Further analysis by compound class also revealed that the average $f_{u,hep}$ fold difference for all species relative to the rat was consistently within 2-fold for all classes (Supplemental Fig. 1). These results indicate the same conclusion: Using the hepatocytic binding in a single species (rat) can be used as a reasonably accurate estimate for other species.

It should be noted, however, that one compound, amiodarone, exhibited a distinctly different free fraction in human liver microsomes and hepatocytes compared with the other species tested. The fraction unbound was approximately 10-fold greater in human microsomes and 20-fold greater in human hepatocytes compared with the averages of the mouse, rat, dog, and monkey. This observation of distinctly higher binding levels in humans relative to other species was also reported previously (Zhang et al., 2010). These authors argued that the observed interspecies difference in amiodarone microsomal binding cannot be

TABLE 2

$F_{u,hep}$ for 36 compounds across five species

A, B, N, and Z correspond to acid, base, neutral, and zwitterionic compound classes, respectively. Values represent a mean of duplicate determinations.

Compound	Class	LogD	Mouse	Rat	Dog	Monkey	Human
Bumetanide	A	−0.080	1.0	0.94	0.93	0.97	1.0
Cefazolin	A	−4.4	0.97	1.0	1.0	0.93	1.0
Cefoperazone	A	−1.1	0.14	0.15	0.18	ND	0.15
Diclofenac	A	1.4	0.84	0.95	0.65	0.72	0.97
Fluvastatin	A	−2.2	0.42	0.58	0.52	0.51	0.53
Gemfibrozil	A	1.7	1.0	1.0	1.0	1.0	1.0
Glyburide	A	1.1	1.0	1.0	0.69	0.80	0.84
Ketoprofen	A	−0.16	0.98	1.0	1.0	1.0	1.0
Naproxen	A	0.35	0.89	0.99	1.0	1.0	1.0
Oxapropin	A	0.090	1.0	1.0	1.0	1.0	1.0
Phenytion	A	−0.71	1.0	0.96	0.76	0.48	0.99
Tenoxicam	A	−2.9	1.0	1.0	1.0	1.0	0.93
Amiodarone	B	5.9	0.0023	0.0081	0.0060	0.0062	0.12
Amitriptyline	B	2.7	0.19	0.24	0.34	0.31	0.32
Bupivacaine	B	2.9	0.85	0.96	0.92	0.92	0.94
Chlorpromazine	B	3.2	0.055	0.14	0.12	0.14	0.17
Clozapine	B	3.5	0.33	0.50	0.45	0.45	0.50
Disopyramide	B	−0.070	1.0	0.98	0.97	1.0	0.99
Haloperidol	B	2.9	0.51	0.76	0.70	0.81	0.81
Imatinib	B	2.5	0.36	0.79	0.72	0.67	0.79
Imipramine	B	2.4	0.34	0.37	0.42	0.33	0.37
Metoprolol	B	−0.47	0.92	0.95	1.0	1.0	1.0
Nicardipine	B	4.6	0.038	0.062	0.051	0.034	0.076
Propranolol	B	0.79	0.71	0.69	0.86	0.94	0.82
Albendazole	N	3.0	0.55	0.70	0.68	0.69	0.74
Antipyrine	N	0.44	0.98	1.0	0.89	1.0	1.0
Dexamethasone	N	−4.6	0.82	0.95	0.96	0.95	0.95
Indapamide	N	3.7	0.14	0.15	0.18	ND	0.15
Isradipine	N	2.0	0.22	0.34	0.34	0.32	0.43
Zidovudine	N	0.050	1.0	1.0	0.98	0.94	0.97
Doxorubicin	Z	−1.5	0.023	0.086	0.031	0.11	0.11
Levofloxacin	Z	−0.39	0.94	0.98	0.97	0.99	0.98
Methotrexate	Z	−5.1	1.0	1.0	1.0	1.0	1.0
Naltrexone	Z	1.6	0.90	0.98	0.98	1.0	0.99
Telmisartan	Z	3.49	0.40	0.54	0.47	0.44	0.44
Topotecan	Z	−0.32	0.87	0.73	0.81	0.90	0.71

Fig. 2. Comparison of fraction unbound ($f_{u,hep}$) in the mouse, rat, dog, or monkey and human liver hepatocytes for 12 acidic (closed circles), 12 basic (closed squares), six neutral (open diamonds), and six zwitterionic drugs (closed triangles). Solid and dashed lines represent lines of unity and 2-fold upper and lower bound limits, respectively.

explained based on the physicochemical properties since a structurally similar tamoxifen, an amphipathic amine with similar lipophilicity (clogD 6.6), demonstrated less than 3-fold binding difference. Similarly, in our study, nicardipine with logD 4.6 demonstrated comparable binding (<2-fold difference) across species, which was in agreement with Zhang et al.'s argument that physicochemical properties alone cannot explain the binding difference of amiodarone; however, these data may reflect targeted binding of amiodarone to a specific protein that is either absent or expressed at a lower abundance in humans. Alternatively, since amiodarone is highly lipophilic and known to interact strongly with lipid bilayers (Rusinova et al., 2015), we hypothesize that the difference in lipid composition between human and preclinical species may lead to the observed discrepancy in nonspecific binding. In line with this, previous measurements have shown that human liver microsomes contain twice the amount of total lipid content relative to the rat in addition to differential fatty acid composition (Benga et al., 1983). To our knowledge, the lipid and fatty acid compositions of other species have not been critically investigated. Follow-up studies to understand the binding difference of amiodarone and similar compounds are in progress and will be reported in due time. Amiodarone as an outlier demonstrates that although there is generally a lack of interspecies differences with respect to nonspecific microsomal and hepatocyte binding for most small molecules, there still may be a minority of compounds that exhibit pronounced species dependence; thus, caution should be exercised when interpreting discovery data, particularly for basic compounds with high lipophilicity. Hence, we recommend periodic spot checking of compounds in a new chemical series to confirm no appreciable interspecies difference.

Besides the single species surrogate approach described herein, other resource-conserving approaches relying on computational methods have been evaluated. Several empirical relationships for the prediction of unbound fraction in microsomal incubations have been proposed (Austin et al., 2002; Hallifax and Houston, 2006; Turner et al., 2006). The empirical relationships were developed using same set of compounds and had demonstrated good predictability. More recently, a fragment-based empirical approach to predict microsomal binding was reported (Nair et al., 2016). The authors were able to reliably

predict nonspecific binding of 114 of 120 compounds, but the method was not successful to predict binding of steroids (neutral) or morphinan nucleus incorporating a 4-5 epoxy ring (base), indicating the need for further refinement on the predictive models. Additionally, a mechanistic tool to predict nonspecific binding of drugs in liver microsomes using a similar set of drugs was discussed (Poulin and Haddad, 2011), and the accuracy of prediction was found to be comparable to the empirical methods. The empirical relationships rely solely on lipophilicity parameters (logP/D) of the drugs, and experimental determination of the logP/D is recommended (Poulin and Haddad, 2011). The universal utility of these *in silico* approaches has not been well evaluated, and up to 10-fold error on predictability has been documented (Poulin and Haddad, 2011). Consequently, *in silico* models are generally used as a complement to experimental measurements, not as a replacement for them (Gao et al., 2010).

In conclusion, microsomal and hepatocyte nonspecific binding was measured across mouse, rat, dog, monkey, and human species using a chemically diverse library of 36 small molecules. Overall, 86% and 92% of the compounds measured in mice, dogs, monkeys, and humans were within 2-fold of rat values for $f_{u,mic}$ and $f_{u,hep}$, respectively. One compound, amiodarone, exhibited unique species-dependent binding; the fraction unbound was approximately 10-fold greater in human microsomes and 20-fold greater in human hepatocytes compared with the average of other species. The aggregate of these data indicates that using a single species $f_{u,mic}$ and $f_{u,hep}$ as a surrogate for other species is sensible for most compounds. As such, we recommend measuring rat $f_{u,mic}$ and $f_{u,hep}$ in the drug-discovery setting and using this value as a proxy for preclinical species and humans. To exercise caution, we recommend periodically spot checking compounds in a new chemical series to confirm no appreciable interspecies difference. Overall, this workflow will mitigate the resource burden in drug discovery while maintaining the integrity and confidence of IVIVC.

Acknowledgments

We thank Brooke M. Rock, Dan A. Rock, and Josh T. Pearson for helpful discussions and review of this work.

Pharmacokinetics and Drug
Metabolism, Amgen Inc., South San
Francisco, California

JOHN T. BARR
JULIE M. LADE
THUY B. TRAN
UPENDRA P. DAHAL

Gao H, Steyn SJ, Chang G, and Lin J (2010) Assessment of in silico models for fraction of unbound drug in human liver microsomes. *Expert Opin Drug Metab Toxicol* **6**:533–542.

Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. *Drug Metab Dispos* **34**:724–726, author reply 727.

Heuberger J, Schmidt S, and Derendorf H (2013) When is protein binding important? *J Pharm Sci* **102**:3458–3467.

Nair PC, McKinnon RA, and Miners JO (2016) A fragment-based approach for the computational prediction of the nonspecific binding of drugs to hepatic microsomes. *Drug Metab Dispos* **44**:1794–1798.

Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. *Drug Metab Dispos* **25**:1359–1369.

Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* **27**:1350–1359.

Poulin P and Haddad S (2011) Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. *J Pharm Sci* **100**:4501–4517.

Riccardi K, Ryu S, Lin J, Yates P, Tess D, Li R, Singh D, Holder BR, Kapinos B, Chang G, et al. (2018) Comparison of species and cell-type differences in fraction unbound of liver tissues, hepatocytes, and cell lines. *Drug Metab Dispos* **46**:415–421.

Rusinova R, Koeppe RE II, and Andersen OS (2015) A general mechanism for drug promiscuity: studies with amiodarone and other antiarrhythmics. *J Gen Physiol* **146**:463–475.

Turner DB, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. *Drug Metab Rev* **38**:162.

Zhang Y, Yao L, Lin J, Gao H, Wilson TC, and Giragossian C (2010) Lack of appreciable species differences in nonspecific microsomal binding. *J Pharm Sci* **99**:3620–3627.

Authorship Contributions

Participated in research design: Barr, Lade, Tran, Dahal.
Conducted in vitro experiments: Barr, Lade, Tran, Dahal.
Performed data analysis: Barr, Lade, Tran, Dahal.
Wrote or contributed to the writing of the manuscript: Barr, Lade, Tran, Dahal.

References

Austin RP, Barton P, Cockcroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. *Drug Metab Dispos* **30**:1497–1503.

Benga G, Pop VI, Ionescu M, Hodárnău A, Tilinca R, and Frangopol PT (1983) Comparison of human and rat liver microsomes by spin label and biochemical analyses. *Biochim Biophys Acta* **750**:194–199.

European Medicines Agency (EMA) (2012) *Guidance on the investigation of drug interactions*, Committee for Human Medicinal Products, London, UK.

Food and Drug Administration (FDA) (2012) *Guidance for Industry Drug Interaction Studies -Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations*, Center for Drug Evaluation and Research, Silver Spring, MD.

Food and Drug Administration (FDA) (2017) *Guidance for Industry In Vitro Metabolism- and Transporter- Mediated Drug-Drug Interaction Studies*, Center for Drug Evaluation and Research, Silver Spring, MD.

Address correspondence to: Upendra P. Dahal, Pharmacokinetics and Drug Metabolism, Amgen Inc., 1120 Veteran's Blvd., South San Francisco, CA 94080.
E-mail: udahal@amgen.com